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ABSTRACT
Objective: To investigate the acceptability of the
Cytosponge, a novel sampling device to detect Barrett’s
oesophagus (BE), a precursor to oesophageal
adenocarcinoma (EAC), among people with risk factors
for this condition.
Design: A qualitative study using semistructured
interviews and focus group discussions. Data were
explored by three researchers using thematic analysis.
Setting: Community setting in London, UK.
Participants: A recruitment company identified
33 adults (17 men, 16 women) aged 50–69 years
with gastro-oesophageal reflux disease (GERD),
a risk factor for BE. The majority of participants
were white British (73%). The focus groups were
stratified by gender and education. 10 individuals
were interviewed and 23 participated in four focus
groups.
Results: 3 key themes emerged from the data: the
anticipated physical experience, preferences for the
content of information materials and comparisons with
the current gold-standard test. Overall acceptability was
high, but there was initial concern about the physical
experience of taking the test, including swallowing and
extracting the Cytosponge. These worries were reduced
after handling the device and a video demonstration of
the procedure. Knowledge of the relationship between
GERD, BE and EAC was poor, and some suggested
they would prefer not to know about the link when
being offered the Cytosponge. Participants perceived
the Cytosponge to be more comfortable, practical and
economical than endoscopy.
Conclusions: These qualitative data suggest the
Cytosponge was acceptable to the majority of
participants with risk factors for BE, and could be used
as a first-line test to investigate GERD symptoms.
Concerns about the physical experience of the test
were alleviated through multimedia resources. The
development of patient information materials is an
important next step to ensuring patients are adequately
informed and reassured about the procedure. Patient
stakeholders should be involved in this process to
ensure their concerns and preferences are considered.
Trial registration number: ISRCTN68382401;
pre-results.
INTRODUCTION
In the UK, 8784 individuals were diagnosed
with oesophageal cancer in 2013.1 The
majority of oesophageal cancers occur as
either squamous cell carcinomas or adeno-
carcinomas (EACs), two cancers with differ-
ent aetiologies.2 EAC mainly originates from
Barrett’s mucosa. Barrett’s oesophagus (BE),
a precursor of EAC, is a complication of
chronic gastro-oesophageal reﬂux disease
(GERD), where the stomach contents rise
into the oesophagus often due to a malfunc-
tioning lower oesophageal sphincter muscle.
The reﬂux of acid and bile damages the
squamous cells lining the oesophagus, which
are then repaired through metaplastic col-
umnar epithelium instead of the regener-
ation of more squamous cells.3 The risk of
malignant progression is low, with an esti-
mated annual incidence of EAC of 0.1–0.5%
in individuals with BE.4–6
Strengths and limitations of this study
▪ This is the first study to qualitatively explore the
acceptability of the Cytosponge test among
members of the public who may be at increased
risk for Barrett’s oesophagus.
▪ The sample was diverse in terms of gender and
educational background.
▪ Participants were recruited using a market
research company, so results may represent the
views of particularly motivated individuals and
should be carefully generalised to the wider
patient population.
▪ Participants were not attending a medical
appointment, so their attitudes towards the
Cytosponge were hypothetical and may not
reflect their opinions in a clinical setting.
▪ Quantitative data on the acceptability of the
Cytosponge and its influence on test uptake were
not assessed, but this has been previously exam-
ined in a clinical setting.
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Risk factors for BE include male gender, Caucasian
ethnicity, over 50 years of age, and having a family
history of BE. Lifestyle factors include being overweight
or obese, high abdominal fat, smoking and drinking
alcohol.7–9 US and UK data suggest approximately one
in ﬁve adults experience GERD in their lifetime,10 and
5–20% of adults with GERD are affected by BE.11 12 BE
is an asymptomatic condition that is usually only discov-
ered during endoscopy performed for evaluation of
GERD symptoms. The majority of EACs, however,
present de novo without a prior diagnosis of BE,13 and
symptomatically detected EACs are normally advanced.
In the UK, the overall EAC 5-year survival rate is as low
as 19%.14
Identifying patients with undiagnosed BE may reduce
mortality; however, routinely investigating all patients
with dyspepsia and GERD using endoscopy would be
time and resource intensive, and not feasible in the
National Health Service (NHS).14 The Cytosponge is a
non-endoscopic, ingestible oesophageal sampling
device, which is both minimally-invasive and potentially
cost-effective.15 16 It can be administered in various set-
tings including primary care. Patients with a history of
GERD symptoms are asked to swallow a gelatine capsule
on a string, which dissolves in the stomach. As the
capsule dissolves a small sponge expands and is pulled
out of the mouth, collecting cells from the oesophagus
in the process. The Cytosponge takes 5 min to adminis-
ter. Immunohistochemistry is performed on the sponge
to detect Trefoil Factor 3 (TFF3), a biomarker for BE.
The acceptability and accuracy of the Cytosponge-
TFF3 test for screening for BE has been tested in several
studies, including the Barrett’s Oesophagus Trial 1
(BEST1), a cohort study in patients with previous pre-
scriptions for acid suppressants in a UK primary care
setting,16 and BEST2, a case–control study in patients
with GERD with or without BE in a UK hospital
setting.17 It was shown to have high sensitivity (73.3%
and 79.9%, respectively) and speciﬁcity (93.8% and
92.4%, respectively) for detecting BE. Moreover, over
93% of patients successfully swallowed the Cytosponge
and 82% reported low levels of anxiety before the test,
suggesting high acceptability. We are currently in the
process of setting up a randomised control trial, BEST3,
to evaluate if the Cytosponge-TFF3 test leads to an
increase in the number of patients diagnosed with BE in
primary care, and to gain an in-depth understanding of
the associated health economics. The acceptability of
the procedure and preferences regarding the presenta-
tion of information on the test are an important part of
this process, and has not been investigated in any detail
until now.
To ensure information on the procedure will be pre-
sented to BEST3 participants in the most accessible
manner, and to encourage rapid implementation in clin-
ical practice at a later stage, public perceptions of the
procedure need to be explored in greater depth. The
aim of this study was to obtain a detailed understanding
of the acceptability of the Cytosponge-TFF3 test in a
sample of individuals with GERD. This population was
chosen because they reﬂect the population to which the
test will be offered as part of the BEST3 trial and if it is
implemented in routine primary care.
METHODS
Participants
The study was advertised to adults aged 50–69 years by a
recruitment company email, and respondents were
screened on the telephone for eligibility. This age group
was selected as this population will be eligible for the
Cytosponge test within the BEST3 trial. GERD severity
was assessed using the GERD impact scale.18 Individuals
were eligible if they experienced one of ﬁve GERD symp-
toms (eg, heartburn), or used GERD medications,
‘sometimes’, ‘often’ or ‘daily’. Individuals with a medical
occupation or previous cancer diagnosis were excluded.
The recruitment company were provided with quotas to
ensure at least half the sample were men and half did
not have an academic degree. Respondents with an aca-
demic degree were classiﬁed as having a high level of
education. The number of people who were approached
or refused is not known.
The ﬁrst 10 eligible respondents were invited to par-
ticipate in a one-to-one interview with a researcher
(MF). The interviews were used to inform the focus
group presentation. After 10 interviews were completed
four focus groups were arranged. The focus groups were
stratiﬁed by gender (male and female) and education
(high vs basic). Participants were recruited until data sat-
uration was reached and no new themes emerged from
the focus groups or interviews.19
Procedure
Semi-structured interviews are an effective method for
obtaining detailed opinions of an isolated individual,
whereas focus groups generate discussion from multiple
perspectives. A combination of both face-to-face inter-
views and focus group discussions were used for this
study to explore how individuals perceived the
Cytosponge test when they were alone and in a group
setting. Interviews and focus group discussions took
place in meeting rooms at the Wolfson Institute for
Preventive Medicine, Queen Mary, University of London.
Written consent was obtained at the beginning of the
interview or focus group by a female research assistant
trained in qualitative research (MF, MSc Health
Psychology). The interviewer had not met any partici-
pant prior to the study, and participants were given little
information beyond her research interests. MF had no
personal interest in oesophageal cancer research that
would inﬂuence her behaviour towards the participants.
No other person was present within the interview or
focus group. A demographic and lifestyle questionnaire
was completed prior to starting. This assessed GERD
severity and management with the GERD impact scale,18
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as well as experience of endoscopy, age, ethnicity, educa-
tion and smoking status. All interviews and focus group
discussions were audio recorded. Participants were com-
pensated £40 for their time and travel. The consolidated
criterion for reporting qualitative research was used.20
Interviews
The interview schedule was designed by the research
team and tested with three adults aged over 50 years to
ensure participants could follow all questions in the dif-
ferent sections. In response to these test interviews back-
ground sections were expanded or simpliﬁed where
necessary and a small number of questions about the
Cytosponge were added. These interviews, however, were
not recorded or included in the analysis.
The interview schedule had six sections, also see
online supplementary document 1: participants’ under-
standing of GERD and its association with BE and EAC,
their ﬁrst impressions of the Cytosponge test, their per-
ceptions of the BEST3 trial, their attitudes towards
endoscopy, the potential impact of cancer prevention on
their decision-making (table 1). At prespeciﬁed points
of the interview, photographs of the Cytosponge were
shown (ﬁgure 1), as well as physical examples of the
device and a video of a patient undergoing the
Cytosponge test.
Focus groups
A presentation was created by the research team. This
followed a similar structure to the interview schedule,
although questions relating to the topic of ‘Cancer
Prevention’ were removed, as participants had difﬁculty
answering these in the interviews. The presentation con-
tained more visual cues than the interview and partici-
pants could read the text, which was in bullet-point
format, and projected onto a screen (see online
supplementary document 2). As with the interviews,
photographs (ﬁgure 1), physical examples and a video
of the Cytosponge test were shown at prespeciﬁed
points. Each focus group was moderated by MF who was
Table 1 Summary of interview schedule
Summary of interview schedule
Understanding of
GERD
▸ Discussion about GERD and other symptoms
– Causes, risk factors, consequences, self-management, treatments, help-seeking
Links between
conditions
▸ Awareness of BE and explanation of link with GERD and oesophageal cancer
Cytosponge test ▸ Verbal and photographic description of Cytosponge
▸ First impressions of Cytosponge based on images
– Willingness to have test, preferences for terminology used, aesthetics of Cytosponge, barriers to
use
▸ Show Cytosponge (capsule and sponge)
– Impressions after demonstration
▸ Video of Cytosponge test https://www.youtube.com/watch?v=s7X9z6qlNUI
– Impressions after video
BEST3 trial ▸ Willingness to take part in trial (if offered)
– Perceptions of test accuracy, risks, practicalities of trial, information preferences
Endoscopy ▸ Diagram of endoscopy
▸ Experiences of endoscopy
▸ Test preferences: Cytosponge vs endoscopy
Cancer prevention ▸ Potential impact of new cancer prevention methods on willingness to have the Cytosponge
BE, Barrett’s oesophagus; BEST3, Barrett’s Oesophagus Trial 3; GERD, gastro-oesophageal reflux disease.
Figure 1 Cytosponge images used in interviews and focus
groups. (A) Cytosponge in gelatine capsule (left) and
expanded (right); (B) Cytosponge in gelatine capsule attached
to string and cardboard as would be used for the Cytosponge
procedure.
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supported by a second member of the research team
(SS or AM). Notes were taken by the second researcher.
Analysis
Interviews and focus group recordings were transcribed
verbatim by MF. Thematic analysis, a technique for
identifying patterns (themes) within qualitative data was
used for the analysis.21 Transcripts were read by MF, SS
and JO to familiarise themselves with the data. The tran-
scripts were then coded by MF to identify initial themes
in the data. Using these themes, MF and SS created
an analytical model on which to base the remaining
analysis. Themes within the model were revised by MF,
SS and JO iteratively throughout the analysis.
Representative quotes were chosen to illustrate the
themes identiﬁed within the data set. Consideration was
given to ensure all sociodemographic groups were
adequately represented in the quotations. It was agreed
by the three researchers involved in the analysis that
data saturation had been reached, and no further inter-
views or focus group discussions were necessary.
Participants were not given an opportunity to review the
transcripts. Microsoft Excel was used to support the
analysis.
RESULTS
Sample characteristics
Thirty-three individuals participated in the study, 16
women and 17 men (table 2). Ages ranged from 50 to
69 years, with a mean age of 57 years. The majority of
participants were white British (73%), approximately
half of them were educated to degree level (52%), and
45% of the sample had experience of endoscopy.
Sampling of roughly equal numbers of participants with
previous experience with endoscopy occurred by chance
rather than through purposive sampling. Ten individuals
were interviewed and 23 took part in focus groups.
Interviews ranged in length between 26 and 57 min, and
focus group discussions between 64 and 86 min, with
participants spending the longest discussing their per-
sonal heartburn experience and their impression of the
Cytosponge.
Participants expressed enthusiasm about the
Cytosponge, with most indicating they would take the
test if invited. The three major themes identiﬁed were
the anticipated physical experience, information prefer-
ences and comparisons with endoscopy. Subthemes are
presented below, along with representative quotes.
Anticipated physical experience
Individuals discussed their anticipated physical experi-
ence of the Cytosponge test. This included swallowing
the Cytosponge and extracting it. The anticipated phys-
ical experience appeared to be shaped by both handling
examples of the capsule and sponge, and watching the
video of the test being carried out.
Swallowing the sponge
Based on initial images and verbal descriptions most
individuals imagined the capsule to be bigger than its
actual size. People expressed surprise and felt reassured
after handling a Cytosponge. It was generally felt that
the act of swallowing the Cytosponge capsule would not
be problematic, because it was of a similar size and
shape to other tablets they take regularly.
It’s smaller than I imagined … The capsule is just like a
normal vitamin capsule, so that’s perfectly ﬁne
(Participant 4, Focus Group 3, female, age 56, high
education)
A few people were concerned about swallowing the
string attached to the capsule.
It’s just the string following it down I think I might have
a problem with. I’ve never actually swallowed a ball of
string (Participant 4, Focus Group 2, male, age 51, basic
education)
Extracting the sponge
After feeling an expanded Cytosponge in the demon-
stration, participants said it was rougher than they
expected, with many comparing it to a ‘Brillo pad’. As a
result, there was concern that an expanded Cytosponge
would damage their oesophagus when it was extracted.
You’re going to feel it, it’s going to be as if somebody’s
got their ﬁngers and scratching the inside of your
Table 2 Demographic characteristics for study
participants (n=33)
n (%)
Gender
Female 16 (48.5)
Male 17 (51.5)
Age (years)
50–59 23 (69.7)
60–69 10 (30.3)
Highest level of education
O-Levels 10 (30.3)
A-Levels 6 (18.2)
Degree 17 (51.5)
Ethnicity
White British 24 (72.7)
White Irish 1 (3.0)
White and Asian 1 (3.0)
Caribbean 1 (3.0)
Missing 6 (18.2)
Smoking status
Smoker 6 (18.2)
Ex-smoker 9 (27.3)
Never smoked 12 (36.4)
Missing 6 (18.2)
Previous experience of endoscopy
Yes 15 (45.5)
No 18 (54.5)
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windpipe (Participant 6, Focus Group 2, male, age 56,
basic education)
Some people were worried they would gag or even
vomit when the Cytosponge was withdrawn from the
stomach.
I’d be frightened that I’d throw up. I’ll be honest
(Participant 5, Focus Group 4, female, age 55, basic
education)
A consistent concern was the possibility of the string
breaking and the Cytosponge getting stuck in the
oesophagus or stomach.
What if it got stuck? Because you know sometimes when
a sweet goes down the wrong way…and it gets stuck?
That is scary (Participant 2, Focus Group 3, female, age
52, high education)
Video reassurance
After watching the video, individuals were more positive
about the Cytosponge test compared with their initial
reactions. The main reason for this attitude shift was
because the extraction of the sponge was considerably
quicker than expected.
In my mind I was thinking of you know [removing the
sponge would be like] catching a ﬁsh (Participant 5,
Focus Group 2, male, age 50, basic education)
Additionally, the ease with which the patient swallowed
the Cytosponge was commented on. The fact the patient
did not gag during its extraction was considered
comforting.
He didn’t show any gagging or anything. He was abso-
lutely ﬁne (LK, Interview, female, age 59, basic education)
Finally, people commented that seeing the patient in
the video looking relaxed put them at ease.
He looked very relaxed, surprisingly… I think I’m sort of
happier now, after watching the video (Participant 6,
Focus Group 1, male, age 60, high education)
Information preferences
Individuals differed in their preferences for what infor-
mation they would receive if they were asked to do the
Cyosponge test. This included the amount of informa-
tion they were given on the link between GERD, BE and
EAC, on the Cytosponge test itself, whether they were
shown an expanded Cytosponge before taking the test,
and the optimal timing for informing patients about
endoscopy referral. People also discussed their preferred
format for communicating information.
Information on cancer link
Most participants had no or low awareness of the rela-
tionship between GERD, BE and EAC.
I’ve never taken it [GERD] to the next step in my mind
(Participant 2, Focus Group 3, female, age 52, high
education)
Some people said they would want to be told GERD
can lead to EAC before they took the Cytosponge test,
while others said they would not want to know
about the association. Some perceived that discussing
a link with cancer may frighten patients and reduce
uptake.
If you’re reading something with ‘cancer’, you’re frigh-
tening them anyway… You say cancer, people won’t take
the pill (Participant 1, Focus Group 2, male, age 58, basic
education)
Information on Cytosponge test
Most participants felt the amount of information pro-
vided about the Cytosponge test during the interview or
focus group was sufﬁcient for them to decide whether
they would have the Cytosponge test.
I’d want to know everything you told us here [referring
to earlier verbal descriptions, sample demonstrations and
the video]. … What it does, how it does it, why you’re
doing it? (Participant 4, Focus Group 2, male, age 51,
basic education)
In addition, some people wanted to be informed
about other details for example whether the test had
to be performed on an empty stomach. There was also
demand for information on side effects, even though
they felt that those would probably be unlikely or
mild.
If there was any side effect, whether it has to be done on
an empty stomach, like, you know, should it be done in
the morning? (Participant 5, Focus Group 4, female, age
55, basic education)
Other information people felt should be included
regarded timings, speciﬁcally how long the test takes in
total, how long the sponge stays in the stomach and the
time it takes to receive results.
Yeah, so what happens? Once it goes to the lab, how long
will it take before you ﬁnd out whether you’ve got it?
(Participant 6, Focus Group 3, female, age 54, high
education)
Furthermore, individuals felt that information on the
accuracy of the test should be included.
I’d want to know how, like I say, I’d want to know how
accurate it is as well. There’s no point doing it if it’s not
accurate (Participant 4, Focus Group 2, male, age 51,
basic education)
Demonstration of Cytosponge test
During the demonstration, some participants expressed
surprise at the appearance of the Cytosponge after the
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capsule had dissolved and it had expanded. They felt
that prospective patients would be unnerved by its
change in appearance if they had not been shown how
the Cytosponge looks after it has been extracted before
the test.
If they don’t tell you, you’re going to be in for a fright
when you pull it out of your throat (Participant 4, Focus
Group 2, male, age 51, basic education)
One person conceded this may not be necessary, and
that a similar approach would not be taken with other
medical procedures.
They wouldn’t do that with any other test, would they?
They wouldn’t let you feel the needle before they took
your blood (Participant 2, Focus Group 3, female, age 52,
high education)
Another approach would be to offer each patient a
choice.
I think it would be nice to be offered the choice. Maybe
be asked ‘would you like to see how it looks? (Participant
5, Focus Group 2, male, age 50, basic education)
Test outcomes
There was debate over whether or not one should be
told before taking the Cytosponge test that a positive
result will necessitate further investigation. Some people
insisted they would expect to be fully informed about
the whole process at the outset, and compared it with
the existing NHS screening programmes.
I imagine it’s just like NHS screening actually, when you
have a mammogram you’re actually told what the pro-
gramme is (Participant 5, Focus Group 3, female, age 60,
high education)
Others felt they would prefer to be told this informa-
tion in a step by step approach, only being informed
about the need for endoscopy after they have received a
positive result. This preference was perceived to prevent
unnecessary anxiety.
I think that just having one test is scary enough for
someone, thinking they might have cancer. So just stick
to that test, and when the results come back, then they
can be told what the next step is (LK, Interview, female,
age 59, basic education)
Information format
Peoples’ preferences for the modality in which informa-
tion about the Cytosponge test was delivered varied.
Suggestions included pictures, a leaﬂet, a website and
a video. The preferred modality was an information
leaﬂet with a website link to the video of the test being
carried out.
A link within the leaﬂet that you can actually go and see
that video of the guy. I think that’s really important
(Participant 2, Focus Group 1, male, age 53, high
education)
A video was perceived by some individuals as being
easier to understand than written information.
Sometimes if it’s late at night and my brain has, sort of,
had enough for the day, I’d much rather just watch a little
clip, you know I can get to see, and I can listen, I don’t
have to read… reading is something you really have to
really concentrate. So, the clip is almost doing it all for
you (RH, Interview, female, age 54, basic education)
One participant mentioned that she would also like to
see a follow-up video of the patient so that she would
know what to expect after the test had been performed.
I would like to see him saying how he feels the next
day… just another follow-up video…you know, ‘I’ve got a
really bad sore throat, and, I feel a bit raw down there
(AL, Interview, female, age 51, high education)
Comparisons with endoscopy
While the Cytosponge test is not intended to replace
endoscopy, it was felt that the new device was preferable
physically, practically and economically.
Discomfort
Fifteen participants had previously undergone endosco-
pies for their heartburn, and almost all reported an
unpleasant experience. By comparison, the Cytosponge
test was perceived to be a more comfortable procedure.
The last [endoscopy] the nurse had to practically sit on
me to stop me moving, because it was so unpleasant. And
I was just regurgitating all this sort of yellow stuff, it was
like something from a horror ﬁlm (GC, Interview, male,
age 51, high education)
[The Cytosponge] is such an innocuous test. You swallow
a pill, you pull it out, two weeks later, done. I can’t see
anybody saying no to that (IF, Interview, male, age 55,
high education)
Practical factors
Individuals were enthusiastic that the Cytosponge test
would be a quicker procedure than endoscopy, could be
carried out by their general practitioner, and would not
require an anaesthetic.
It’s quicker, my doctor can do it and there’s no messing
around, no hospital appointments (AL, Interview,
female, age 51, high education)
The fact that people would be able to resume their
everyday activities immediately after the procedure was
also seen as a beneﬁt.
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You can walk out of the doctor’s surgery… you can get
on with your everyday life (Participant 5, Focus Group 4,
female, age 55, basic education)
Economic factors
A minority of people considered the superior cost-
effectiveness of the Cytosponge test, and the beneﬁts
this would have for the healthcare system.
That’s going to be an awful lot cheaper to do than an
endoscopy at an hour a go with a gastroenterologist (KP,
Interview, female, age 58, basic education)
DISCUSSION
In this sample of UK adults with GERD, the Cytosponge
test was considered to be an acceptable and simple test
to detect BE. Three key themes emerged from the data,
including the anticipated physical experience of the test,
preferences for the format and content of information,
and comparisons with the current gold-standard test.
These data can be used to inform the development of
information materials and assist clinicians communicat-
ing with the public about the test.
Initial reactions to the Cytosponge test focused on the
anticipated physical experience. Common concerns
included worries about swallowing the capsule and
string, the texture of the sponge once the capsule had
dissolved, and the potential for the device to break and
become stuck. Despite these worries, nearly all partici-
pants were reassured by seeing examples of the device
and a video of a previous patient undergoing the pro-
cedure. The observation that participants felt more
inclined to take the Cytosponge test after watching the
video demonstration reﬂects previous research into the
use of multimedia to promote health behaviours,22
including screening attendance.23 Video demonstration
of the test could be an important communicative
approach to reduce test anxiety and promote informed
uptake.
Participants’ information preferences varied. Opinions
differed on how much information should be presented
on the link between GERD, BE and EAC, test outcomes,
and whether an example of an expanded Cytosponge
should be shown. The content of health information
materials is generally driven by the ethical and legal
responsibility to promote informed decision-making.24
The preference of some patients to receive limited infor-
mation therefore creates a tension between respecting
public opinion, while also acting ethically and respon-
sibly. The volume of questions asked by participants in
the study and the variety of preferences suggests care
should be taken during the design and evaluation of
information resources. Ensuring the perspective of
patient stakeholders is considered during this process
may help to accommodate patient preferences.
Evidence-based techniques and strategies for promoting
comprehension should also be used to develop such
resources.25 26
Overall, participants felt that the Cytosponge would be
preferable for potential patients compared with the
current gold-standard test, endoscopy. The device was
considered superior in terms of the physical experience,
the practical simplicity and the potential for economic
savings to the healthcare service. Initial concerns about
the device notwithstanding, public enthusiasm for the
Cytosponge test is encouraging. On the basis of this
initial acceptability study, recruitment of patients to the
BEST3 trial and subsequently implementing the device
within a primary care setting is unlikely to face insur-
mountable barriers from the public.
Our study is the ﬁrst to explore in-depth attitudes
towards the Cytosponge test in a sample of adults with
GERD. The use of interviews and focus groups provided
a rich data set consisting of opinions expressed individu-
ally as well as in a group environment. The sample was
diverse in terms of educational background and gender,
allowing multiple perspectives to be considered. The
study did have limitations. The sample was recruited
using a market research company, and respondents may
have been particularly motivated or interested in the
topic. We did not collect quantitative data on acceptabil-
ity or attitudes towards the test. Finally, the participants
were not attending a medical appointment and there-
fore their attitudes towards the Cytosponge test were
hypothetical, and may not reﬂect the opinions of
patients in a clinical setting.
This study has several implications for clinical practice.
Both for BEST3 and if the Cytosponge test is implemen-
ted in routine care it will be important for information
materials and health professionals to reassure patients
about the procedure. In particular, concerns about the
size of the device, the string breaking and the physical
sensation on the throat when the device is withdrawn
should be addressed. The speed with which the proced-
ure can be completed should be emphasised to prevent
exaggerated assumptions about a lengthy extraction.
The study showed individuals hold strong preferences
regarding the amount and format of information they
are given. Consequently, health professionals should
consider eliciting information preferences during the
consultation. Finally, we demonstrated a need to raise
awareness of the link between GERD, BE and EAC.
Clinicians should not assume that patients are aware of
the associations, and should carefully explain the
context when discussing why recurrent GERD symptoms
should be investigated.
CONCLUSION
This qualitative study revealed adults with GERD consid-
ered the Cytosponge test to be acceptable physically,
practically and economically, as well as being preferred
to endoscopy. If the device is implemented in routine
clinical practice, it will be necessary to reassure patients
about the Cytosponge and provide materials that meet
the information needs of the patient group.
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